A drug-delivery compound born at Kansas University is moving into a new market.
CyDex Inc., a Lenexa-based pharmaceuticals company, announced this week that a drug using its Captisol technology - technology invented at KU's Higuchi Biosciences Center - had been approved by regulators for use in Japan.
Pfizer Japan confirmed that Japanese regulators approved the manufacturing of Vfend, an antifungal product that Pfizer has marketed in the United States and Europe since 2002. Pfizer introduced Vfend intravenous and oral forms last month in Japan, and the I.V. formulation combines the product's active ingredient with Captisol.
Privately held CyDex spun off from the Higuchi center in 1993.